5-O-Methylvisammioside inhibits HMGB1-induced Angiogenesis of hepatocellular carcinoma through RAGE/MEK/ERK signaling pathway
PLOS One · 2025
DOI: 10.1371/journal.pone.0322056 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Wenyue Hou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China. Hauptthemen laut MEDLINE: HMGB1 Protein, Carcinoma, Hepatocellular, Liver Neoplasms, Neovascularization, Pathologic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Suzhou Gusu Health Talent Research Project, the Medical Science Project of Jiangsu Provincial Health and Wellness Commission.
Abstract (Originalsprache)
5-O-Methylvisammioside (5OMV), a flavonol compound derived from the traditional Chinese medicine plant Saposhnikovia divaricat , has been shown to inhibit vasospasm induced by High Mobility Group Box 1 (HMGB1) protein. However, its therapeutic potential and molecular mechanisms in HMGB1-induced tumor angiogenesis remain unexplored. Through comprehensive in vitro assays, we demonstrated that 5OMV significantly attenuates HMGB1-induced proliferation, migration, tube formation, and angiogenic activity in human umbilical vein endothelial cells (HUVECs). Parallel in vivo studies using an orthotopic hepatocellular carcinoma model in C57BL/6 mice revealed that 5OMV treatment markedly reduced tumor progression and microvascular density. Mechanistic studies identified that 5OMV downregulates both total and phosphorylated forms of RAGE, MEK, and ERK in HUVECs and tumor tissues. These findings collectively establish that 5OMV exerts anti-tumor effects in hepatocellular carcinoma through targeted modulation of the HMGB1/RAGE/MEK/ERK signaling axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China.
- College of Life Sciences, Xuzhou Medical University, Xuzhou, China.
- Suzhou Academy of Wu Men Chinese Medicine, Suzhou, China.
ORCID-Profile: Lurong Zhang
Förderung
- National Natural Science Foundation of China
- the Suzhou Gusu Health Talent Research Project
- the Medical Science Project of Jiangsu Provincial Health and Wellness Commission
- the Suzhou Science and Technology Development Program Project
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
Zitieren
APA
Hou, W., Zou, T., Yan, Y., Zhuang, Y., Gao, S., Ju, H., Yao, F., Yuan, Q., Zhou, L., Liang, G., Song, X., & Zhang, L. (2025). 5-O-Methylvisammioside inhibits HMGB1-induced Angiogenesis of hepatocellular carcinoma through RAGE/MEK/ERK signaling pathway. PLOS One. https://doi.org/10.1371/journal.pone.0322056
Vancouver
Hou W, Zou T, Yan Y, Zhuang Y, Gao S, Ju H, et al. 5-O-Methylvisammioside inhibits HMGB1-induced Angiogenesis of hepatocellular carcinoma through RAGE/MEK/ERK signaling pathway. PLOS One. 2025. doi:10.1371/journal.pone.0322056
BibTeX
@article{Hou2025,
author = {Hou, Wenyue and Zou, Ting and Yan, Yichao and Zhuang, Yaolong and Gao, Shaomei and Ju, Huijun and Yao, Fei and Yuan, Qin and Zhou, Liang and Liang, Guoqiang and Song, Xiudao and Zhang, Lurong},
title = {5-O-Methylvisammioside inhibits HMGB1-induced Angiogenesis of hepatocellular carcinoma through RAGE/MEK/ERK signaling pathway},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322056}
}
EUVIMED